In a blow to Bayer, a U.S. federal judge in Manhattan has said he will not block Johnson & Johnson’s survival claims on a key prostate cancer drug.
New data build case for Roche’s oral BTK drug for MS
Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
